Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for the Detection of Primary and Recurrent Bladder Cancer: A Systematic Review and Meta-analysis
Open Access
- 19 June 2024
- journal article
- review article
- Published by Elsevier in European Urology Focus
- Vol. 10 (6) , 922-934
Abstract
No abstract availableKeywords
Funding Information
- Fundação para a Ciência e a Tecnologia (CI-IPOPGEBC_PTDC/EME-APL/1342/2020, SFRH/BD/143717/2019)
- Instituto Português de Oncologia do Porto (PI27-FB-GEBC_CI-IPOP-2016, SuHRBlaC-PI-191-CI-IPOP247020)
This publication has 88 references indexed in Scilit:
- The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder CancerClinical Genitourinary Cancer, 2022
- Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-upWorld Journal of Urology, 2021
- The Paris system of Reporting Urinary Cytology: Strengths and opportunitiesDiagnostic Cytopathology, 2020
- High Detection Rate for Non–Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature TestClinical Genitourinary Cancer, 2020
- Diagnostic predictive value of the Bladder EpiCheck test in the follow‐up of patients with non–muscle‐invasive bladder cancerCancer Cytopathology, 2019
- Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation eventsInternational Journal of Cancer, 2010
- Hypermethylated SFRP1, but none of other nine genes “informative” for western countries, is valuable for bladder cancer detection in mainland ChinaJournal of Cancer Research and Clinical Oncology, 2009
- Discovery of myopodin methylation in bladder cancerThe Journal of Pathology, 2008
- Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patientsInternational Journal of Cancer, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986